Search Results - "Gassull, M"

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management by Dignass, A., Van Assche, G., Lindsay, J.O., Lémann, M., Söderholm, J., Colombel, J.F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., Hommes, D.W., Michetti, P., O'Morain, C., Öresland, T., Windsor, A., Stange, E.F., Travis, S.P.L.

Get full text

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease by Rahier, J F, Ben-Horin, S, Chowers, Y, Conlon, C, De Munter, P, D'Haens, G, Domènech, E, Eliakim, R, Eser, A, Frater, J, Gassull, M, Giladi, M, Kaser, A, Lémann, M, Moreels, T, Moschen, A, Pollok, R, Reinisch, W, Schunter, M, Stange, E F, Tilg, H, Van Assche, G, Viget, N, Vucelic, B, Walsh, A, Weiss, G, Yazdanpanah, Y, Zabana, Y, Travis, S P L, Colombel, J F

Get full text

European evidence-based Consensus on the management of ulcerative colitis: Current management by Travis, S P L, Stange, E F, Lémann, M, Oresland, T, Bemelman, W A, Chowers, Y, Colombel, J F, D'Haens, G, Ghosh, S, Marteau, P, Kruis, W, Mortensen, N J McC, Penninckx, F, Gassull, M

Get full text

European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations by Caprilli, R, Gassull, M A, Escher, J C, Moser, G, Munkholm, P, Forbes, A, Hommes, D W, Lochs, H, Angelucci, E, Cocco, A, Vucelic, B, Hildebrand, H, Kolacek, S, Riis, L, Lukas, M, de Franchis, R, Hamilton, M, Jantschek, G, Michetti, P, O’Morain, C, Anwar, M M, Freitas, J L, Mouzas, I A, Baert, F, Mitchell, R, Hawkey, C J

“…This third section of the European Crohn’s and Colitis Organisation (ECCO) Consensus on the management of Crohn’s disease concerns postoperative recurrence,…”
Get full text

Infliximab safety profile and long‐term applicability in inflammatory bowel disease: 9‐year experience in clinical practice by ZABANA, Y., DOMÈNECH, E., MAÑOSA, M., GARCIA‐PLANELLA, E., BERNAL, I., CABRÉ, E., GASSULL, M. A.

“…Aliment Pharmacol Ther 31, 553–560 Summary Background  Most available data on infliximab therapy come from large, short‐term, pivotal RCTs and concerns about…”
Get full text

Efficacy and safety of short‐term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open‐label, multicentre trial by HINOJOSA, J., GOMOLLÓN, F., GARCÍA, S., BASTIDA, G., CABRIADA, J. L., SARO, C., CEBALLOS, D., PEÑATE, M., GASSULL, M. A.

“…Summary Background The use of tumour necrosis factor antagonists has changed the therapeutic approach to Crohn's disease. Aim To determine response and…”
Get full text

Granulocyteaphaeresis in steroid‐dependent inflammatory bowel disease: a prospective, open, pilot study by Domènech, E., Hinojosa, J., Esteve‐Comas, M., Gomollón, F., Herrera, J. M., Bastida, G., Obrador, A., Ruiz, R., Saro, C., Gassull, M. A.

“…Summary Background : Uncontrolled studies suggest that granulocyteaphaeresis might be useful in the management of active ulcerative colitis. Aim : To assess…”
Get full text

Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? by DOMÈNECH, E., HINOJOSA, J., NOS, P., GARCIA‐PLANELLA, E., CABRÉ, E., BERNAL, I., GASSULL, M. A.

“…Summary Background:  Few data are available regarding the evolution of Crohn's disease after discontinuing a successful course of infliximab. Aim:  To evaluate…”
Get full text

Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial by Gassull, M A, Fernández-Bañares, F, Cabré, E, Papo, M, Giaffer, M H, Sánchez-Lombraña, J L, Richart, C, Malchow, H, González-Huix, F, Esteve, M

“…Background: Dietary fat has been suggested to determine the therapeutic effect of enteral diets in Crohn's disease. Aim: To assess the efficacy of two whole…”
Get full text

Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease by GASSULL, M. A.

“…Summary Undigested carbohydrates reaching the colon can act as competitors for epithelial bacterial receptors, making it difficult for noncommensal bacteria to…”
Get full text

The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes by LLOR, X, PONS, E, ROCA, A, ÀLVAREZ, M, MAÑÉ, J, FERNÁNDEZ-BAÑARES, F, GASSULL, M.A

“…Background and Aims: Several nutrients play a significant role in colorectal cancer development, and fats could be among the most determinant. While several…”
Get full text

Effect of olive oil on early and late events of colon carcinogenesis in rats: modulation of arachidonic acid metabolism and local prostaglandin E2 synthesis by Bartolí, R, Fernández-Bañares, F, Navarro, E, Castellà, E, Mañé, J, Alvarez, M, Pastor, C, Cabré, E, Gassull, M A

“…BACKGROUND Animal model studies have shown that the colon tumour promoting effect of dietary fat depends not only on the amount but on its fatty acid…”
Get full text

Short- and Long-Term Outcome of Severe Alcohol-Induced Hepatitis Treated With Steroids or Enteral Nutrition: A Multicenter Randomized Trial by Cabré, Eduard, Rodrı́guez-Iglesias, Pilar, Caballerı́a, Joan, Quer, Joan C., Sánchez-Lombraña, José L., Parés, Albert, Papo, Michel, Planas, Ramon, Gassull, Miquel A.

“…Steroids are recommended in severe alcohol-induced hepatitis, but some data suggest that artificial nutrition could also be effective. We conducted a…”
Get full text

A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial by Mañé, J, Pedrosa, E, Lorén, V, Gassull, M A, Espadaler, J, Cuñé, J, Audivert, S, Bonachera, M A, Cabré, E

“…Immunosenescence can increase morbi-mortality. Lactic acid producing bacteria may improve immunity and reduce morbidity and mortality in the elderly. We aimed…”
Get full text

Azathioprine without oral ciclosporin in the long‐term maintenance of remission induced by intravenous ciclosporin in severe, steroid‐refractory ulcerative colitis by Domènech, E., Garcia‐Planella, E., Bernal, I., Rosinach, M., Cabré, E., Fluvià, L., Boix, J., Gassull, M. A.

“…Summary Background : Intravenous ciclosporin is considered to be the only alternative to avoid surgery in severe, steroid‐refractory ulcerative colitis. In…”
Get full text

TNFSF15 Polymorphisms Are Associated With Susceptibility to Inflammatory Bowel Disease in a New European Cohort by THIEBAUT, R, KOTTI, S, BINDER, V, FINKEL, Y, PASCOE, L, HUGOT, J.-P, JUNG, C, MERLIN, F, COLOMBEL, J. F, LEMANN, M, ALMER, S, TYSK, C, O'MORAIN, M, GASSULL, M

“…Inflammatory bowel disease (IBD), e.g., Crohn's disease (CD) and ulcerative colitis (UC), is a complex genetic disorder. Tumor necrosis factor (ligand)…”
Get full text

Expression of HLA‐G in inflammatory bowel disease provides a potential way to distinguish between ulcerative colitis and Crohn’s disease by Torres, M. I., Le Discorde, M., Lorite, P., Ríos, A., Gassull, M. A., Gil, A., Maldonado, J., Dausset, J., Carosella, E. D.

“…In addition to being involved in nutrient uptake, the epithelial mucosa constitute the first line of defense against microbial pathogens. A direct consequence…”
Get full text

Clinical outcome of newly diagnosed Crohn’s disease: a comparative, retrospective study before and after infliximab availability by DOMÈNECH, E., ZABANA, Y., GARCIA‐PLANELLA, E., LÓPEZ SAN ROMÁN, A., NOS, P., GINARD, D., GORDILLO, J., MARTÍNEZ‐SILVA, F., BELTRÁN, B., MAÑOSA, M., CABRÉ, E., GASSULL, M. A.

“…Summary Background  Infliximab (IFX) could change the course of Crohn’s disease (CD) by reducing steroid use, surgery or prompting earlier introduction of…”
Get full text

Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis by Pardo, Albert, Bartolí, Ramon, Lorenzo‐Zúñiga, Vicente, Planas, Ramon, Viñado, Belén, Riba, Joan, Cabré, Eduard, Santos, Justiniano, Luque, Teresa, Ausina, Vicenç, Gassull, Miguel A.

“…Deranged intestinal motility, which occurs in cirrhosis, may facilitate the development of intestinal bacterial overgrowth (IBO), which can lead to bacterial…”
Get full text

Cytomegalovirus infection in patients with inflammatory bowel disease by Vega, R., Bertrán, X., Menacho, M., Domènech, E., Moreno de Vega, V., Hombrados, M., Cabré, E., Ojanguren, I., Gassull, M. A.

“…It has been suggested that, in inflammatory bowel disease, cytomegalovirus behaves in the intestine as a nonpathogenic bystander, and even its finding in…”
Get full text